Objective : Diagnosing tumor progression and pseudoprogression remains challenging for many clinicians. Accurate recognition of these findings remains paramount given necessity of prompt treatment. However, no consensus has been reached on the optimal technique to discriminate tumor progression. We sought to investigate the role of magnetic resonance perfusion (MRP) to evaluate tumor progression in glioma patients. Methods : An institutional retrospective review of glioma patients undergoing MRP with concurrent clinical follow up visit was performed. MRP was evaluated in its ability to predict tumor progression, defined clinically or radiographically, at concurrent clinical visit and at follow up visit. The data was then analyzed based on glioma grade and subtype. Resusts : A total of 337 scans and associated clinical visits were reviewed from 64 patients. Sensitivity, specificity, positive and negative predictive value were reported for each tumor subtype and grade. The sensitivity and specificity for high-grade glioma were 60.8% and 87.8% respectively, compared to low-grade glioma which were 85.7% and 89.0% respectively. The value of MRP to assess future tumor progression within 90 days was 46.9% (sensitivity) and 85.0% (specificity). Conclusion : Based on our retrospective review, we concluded that adjunct imaging modalities such as MRP are necessary to help diagnose clinical disease progression. However, there is no clear role for stand-alone surveillance MRP imaging in glioma patients especially to predict future tumor progression. It is best used as an adjunctive measure in patients in whom progression is suspected either clinically or radiographically.
INTRODUCTION
Differentiating post-treatment changes in high-grade gliomas remains a challenging clinical task due to their radiological similarities (recurrent enhancing lesions). The prompt diagnosis of tumor progression and radiation necrosis remains paramount due to the apparent therapeutic and prognostic implications. Accurate diagnoses with conventional MR imaging are limited, as tumor progression appears to strongly mimic entities such as radiation necrosis and pseudoprogression as outlined by the MacDonald criteria 19) . Over criteria has replaced the McDonald criteria to help discriminate these entities more clearly by dividing tumor response into four sets (complete, partial, stable, and progression) 25) .
Recently, it has been demonstrated that accurate identification of tumor progression may be enhanced by adjunct imaging modalities such as magnetic resonance perfusion (MRP), Single photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging [3] [4] [5] 7, 11, 12, 15, 24) . MRP is a unique imaging modality that utilizes gadolinium contrast to expand upon conventional MRI sequencing in order to approximate the blood flow/volume of selected tissues. Neoplasms, due to their high vascularity, tend to demonstrate higher cerebral blood volume (CBV) measurements than normal brain. Radiation necrosis on the other hand tends to demonstrate lower CBV values due to the lower cellularity and lack of neovascularization 8, 16, 22) . Because of its availability at most hospitals, MRP may be an effective tool for rapidly distinguishing these two entities.
Many patients in our institution receive surveillance MRP imaging to evaluate for glioma recurrence. In our institution, it is used in three different scenarios: First, it is used contemporaneously with MR and/or clinical findings suggestive of TP in patients with treated high grade glioma, as an adjunct to determine whether there is true TP or RN or pseudo-progression (PP). Second, it is used contemporaneously with MR and/or clinical findings suggestive of tumor progression in patients with low grade glioma, as an adjunct to determine whether there has been progression to a higher grade of tumor. Finally, it is used as a "screening tool" in patients with any type of glioma and stable clinical and imaging findings, to try to predict progression at a later date. Since there is no consensus in the literature on the utility of MRP in confirming clinical tumor progression for any of the three scenarios, we aimed to elucidate the clinical accuracy of MRP more closely by reviewing our own institutional experience.
MATERIALS AND METHODS

Selection criteria
Following approval for our institutional review board Table 1 .
Contemporaneous clinical visits
For contemporaneous MRP imaging studies and clinical visits, the total PPV, NPV, sensitivity and specificity for both
LGG and HGG were calculated (Table 2) 
Future clinical visits
The ability of MRP to evaluate for tumor progression at the next clinical visit was also assessed. One-hundred and twenty-five MRP studies and associated follow-up clinical visits occurred within 90 days. The PPV, NPV, sensitivity and specificity for all glioma types were calculated (Table 2 ) from the imaging and next follow up visits less than ninety days. Pre- 
DISCUSSION
The results from our review show that as a measure of sur- 
MRP for high-grade gliomas
The contemporaneous use of MRP in conjunction with MR for evaluation of tumor progression in high-grade gliomas has been well characterized in the literature 3, 8, 10, 11, 16, 21, 23) .
The sensitivity and specificity of MRP to predict histological tumor progression in conjunction with MR has been approximately 80% and 77% respectively 24) . Additionally, the utility of MRP increases if a specific cut-off parameter was and MSIVP (maximum slope of enhancement in the vascular phase) respectively 17, 20) . By using MRP alone, the sensitivity and specificity of detecting tumor progression in our series was approximately 61% and 88% respectively. Our series indicates that when using MRP in conjunction with both standard MR and clinical follow-up, the accuracy of MRP increases. However, in our study, specific cut-off parameters
were not utilized to optimize the specificity of our study. Additionally, in comparison to other studies which only used tumor histology as evidence of progression, our study compares MRP to radiographic and clinical progression as well which is more indicative of daily decision-making for neurooncologists as many patients are not-reoperated everytime a MR imaging displayes progression.
MRP for low-grade gliomas
Low grade-gliomas typically may or may not enhance on imaging, and when enhancement is present, anaplastic (WHO Grade III) features may be present. However, after radiation, differentiation of post-treatment enhancement on MR and tumor progression for low-grade gliomas becomes challenging due to their delayed malignant transformation and potential for radiation necrosis 13) . Use of perfusion imaging in these low-grade tumors may detect malignant transformation with reasonable accuracy. In our series, sensitivity and specificity remained high for these lesions using MRP. In addition, other series seem to endorse following changes in CBV for low-grade gliomas to detect anaplastic transformation as early as 1 year prior to the development of contrst-enhancement 6, 9, 18) . However, other modalities may be more efficacious in detecting progression earlier compared to MRP.
Hlaihel et al. noted that magnetic resonance spectroscopy detected tumor progression (based on increased choline/creatine ratio) on average 15 months prior to increases in CBV on MRP 14) . Nevertheless, MRP with contemporaneous MR may be useful if careful cut-off parameters are utilized to detect clinical tumor progression.
Use of MRP as a screening tool
Perfusion imaging as a screening tool to predict malignant transformation in patients with any glioma remains important. In our study, perfusion imaging did not accurately pre- 
Study limitations
Our study was limited in several areas. First, while the criteria for TP was based on RANO criteria, significant increas- Additionally, the utility of perfusion-based imaging dramatically decreases after certain types of treatment such as anti-angiogenic chemotherapeutics and brachytherapy 1, 2) .
Variations in contrast-enhancement patterns after bevacizumab treatment confounds the utility of perfusion imaging.
In our study, a few recurrent tumors were treated with beva- 
